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dyslipidemia in adults” (the new Guide for short)
released by Zhonghua Xin Xue Guan Bing Za Zhi is
based on the 2007 “Guide for Dyslipidemia Prevention
in Chinese Adults” (the 2007 Hyperlipidemia Guide for
short) and is the result of a year's effort and work by a
team of specialists.1
The public release of the 2007 Hyperlipidemia
Guide has had a positive effect on control and man-
agement of hyperlipidemia and atherosclerotic cardio-
vascular disease (ASCVD). In the past decade, there has
been a paradigm shift in international and domestic
research and the viewpoints in this field; thus, a new
guide for dyslipidemia is imperative.
The group of specialists who have formulated the
guides, from the 1997 “Recommendations for Dyslipi-
demia Prevention” to the first dyslipidemia guideline in
China, until the formulation of this new Guide, have
adhered to three principles. First, they used international
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to foreign guides. Second, they adhered to the public
welfare and scientific nature of the guide, with no inter-
ference of various business interests. Third, they embody
authority, as the formulation process for the guide
brought together specialists in the field; scientific de-
mocracy was fully upheld, evidence was thoroughly
collected and evaluated, and authorizationwas granted by
the Disease Prevention and Control Bureau of the Na-
tional Health and Family Planning Commission, China.New situations and challenges faced during formu-
lation of the new Guide
1. The 2007HyperlipidemiaGuidewas primarily based
on results from Chinese epidemiological studies
conducted over many years, with the highlight being
based on the risk stratification for cardiovascular
diseases (including stroke) formulated using our own
data; owing to the high incidence of ischemic stroke
in China, the weight of hypertension in the risk
stratification was increased. Presently, randomized
double-blind clinical studies of dyslipidemia in-
terventions focused on ASCVD in China are still
limited, the only study is Xuezhikang, a partially
purified red yeast rice under controlled pharmaceu-
tical manufacturing conditions, contains a family ofElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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+ MODELnaturally occurring statins (monacolins)emost
prominently monacolin K, which is identical to the
lipid-lowering therapy lovastatin (Mevacor),
addressing the secondary prevention of myocardial
infarction. Since 2007, an increasing number of do-
mestic and international organizations have been
conducting studies on dyslipidemia interventions.
Only the HPS-2 THRIVE results reported by a Chi-
nese/European collaborative group have been used
for over 12,000 Chinese patients.
2. The new Guide for cholesterol and ASCVD pub-
lished by the American College of Cardiology
(ACC) and the American Heart Association (AHA)
at the end of 2013 subverts the American Adult
Treatment Panel (ATP) system and recommends the
removal of low density lipoprotein cholesterol
(LDL-C) and other interventional targets of dysli-
pidemia. The guide lists 4 categories of patients that
require statin treatment and recommends interven-
tion with high doses of a high-potency statin. This
led to consistent questioning and opposition by the
American National Lipid Association, the European
Society of Cardiology, the European Atheroscle-
rosis Society, the International Atherosclerosis So-
ciety, and leading Chinese scholars in the field.
3. In the recent years, a series of incorrect viewpoints
regarding dyslipidemia intervention and ASCVD
prevention driven primarily by business interests, has
emerged in China. One example is the growing
number of the much-hyped small-scale, short
follow-up, exploratory studies in which observations
act as substitutes for endpoints. These one-sided
exaggerated claims of multiple effects (such as
anti-inflammatory effects) outside the primary role
of statins in lowering the cholesterol suggest the
sequential use of 80 mg atorvastatin during the
perioperative period of percutaneous coronary
intervention (PCI) and acute coronary syndrome
(ACS). More seriously, this misconception is already
widely accepted in several country-level hospitals.
The Chinese new Guide is clear, raises the banners of
public welfare and science, adheres to the characteristic
evidence from Chinese studies without following the
ACC/AHA, and strictly rejects and resists intervention
related to business interests.
Main highlights of the new Guide
1. It does not agree with the recommendations of the
ACC/AHA, and clearly adheres to interventionalPlease cite this article in press as: Hu D-Y, New guidelines and evidence a
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risk stratification. Following extensive discussion
and voting, it was recommended that the inter-
ventional LDL-C target value for the secondary
prevention of ASCVD be lowered from
<2.0 mmol/L (80 mg/dl) in 2007 to <1.8 mmol/L
(70 mg/dl). Besides, in order to fully uphold sci-
entific democracy, Prof. Zhao Shuiping, the Sec-
ond Xiangya Hospital of Central South
University, was invited to present his opinions
about not changing the target value of <2.0 mmol/
L (80 mg/dl) in detail.2
2. The new Guide adheres to the scientific theories
and laws about cholesterol known for a hundred
years, and rejects one-sided excessive emphasis on
the multiple effects of statin intervention.
3. The new Guide is based on Chinese data and evi-
dence, and emphasizes that most Chinese patients
do not need and cannot tolerate the high-potency
high-dose statin treatment recommended by the
ACC/AHA. It clearly indicates that the appropriate
unified treatment regimen for Chinese patients is to
use low-potency doses of statins, and drug com-
binations only when needed.
4. The ACS and PCI are not singled out, and the
sequential use of high-potency, high doses of sta-
tins is not recommended.
We congratulate all the authors on the publication of
the new Guide, and are grateful to the cardiovascular
specialists for their dedication to the project. The pub-
lication of the new Guide marks the recognition of a
successful historic collaboration with the China
Cholesterol Education Program (CCEP). The study,
promulgation, and implementation of the new Guide are
the mission and responsibility of our group and the
CCEP. We hope that after the National Conference on
Health and Wellness, the New Guide can mark a new
stage in the prevention of ASCVD.
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